Patent ID: 8148351
Filing Date: 2012-04-03
Classification: A23L,A23V,A61K,A61P

Abstract:
1. A method for ameliorating or treating an inflammatory bowel disease, comprising administering a composition comprising galactomannan in an amount sufficient to lower the activity of myeloperoxidase and TNF-α to a patient suffering from said inflammatory bowel disease, wherein said galactomannan is a degraded galactomannan having an average molecular weight of from 8,000 to 50,000 and a viscosity of 10 mPa·s or less, as determined by 0.5(w/v) % aqueous solution of the degraded galactomannan, wherein the degraded galactomannan is produced by hydrolyzing guar gum with β-mannanase. without further chemical processing, and wherein the administering step includes administering the composition having 5-100% by weight of galactomannan in an amount of 1 to 70g/day/adult.